Cleo Diagnostics (ASX:COV) ROC (Joel Greenblatt) %: -24,852.46% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:COV Cleo Diagnostics Ltd ASX:COV
10 GF Score
Price A$0.35
! 1 Warning Sign
View Full Analysis

What is Cleo Diagnostics ROC (Joel Greenblatt) %?

Cleo Diagnostics ASX:COV -1.41% 10 ROC (Joel Greenblatt) % is -24,852.46% as of Dec. 2025. GuruFocus rates ASX:COV with a GF Score™ of 10/100. The stock has 1 warning sign investors should review. Among 838 Medical Devices & Instruments companies, Cleo Diagnostics ranks worse than 99.4% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Cleo Diagnostics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -24,852.46%.

The historical rank and industry rank for Cleo Diagnostics's ROC (Joel Greenblatt) % or its related term are showing as below:

ASX:COV' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -23032.58   Med: -10665.71   Max: -4260.53
Current: -23032.58

During the past 3 years, Cleo Diagnostics's highest ROC (Joel Greenblatt) % was -4260.53%. The lowest was -23032.58%. And the median was -10665.71%.

ASX:COV's ROC (Joel Greenblatt) % is ranked worse than
99.4% of 838 companies
in the Medical Devices & Instruments industry
Industry Median: 4.145 vs ASX:COV: -23032.58

Cleo Diagnostics's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Cleo Diagnostics  (ASX:COV) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Cleo Diagnostics ROC (Joel Greenblatt) % Related Terms


Cleo Diagnostics ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for Cleo Diagnostics's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cleo Diagnostics ROC (Joel Greenblatt) % Chart

Cleo Diagnostics Annual Data
Trend Jun23 Jun24 Jun25
ROC (Joel Greenblatt) %
-4,260.53 -10,665.71 -15,950.77

Cleo Diagnostics Semi-Annual Data
Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROC (Joel Greenblatt) % Get a 7-Day Free Trial -14,164.38 -6,853.73 -14,273.33 -19,954.10 -24,852.46

ASX:COV vs ABT, SYK, MDT: ROC (Joel Greenblatt) % Comparison

For the Medical Devices subindustry, Cleo Diagnostics's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cleo Diagnostics ROC (Joel Greenblatt) % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cleo Diagnostics's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Cleo Diagnostics's ROC (Joel Greenblatt) % falls into.


ASX:COV
10GF Score
Cleo Diagnostics Ltd ASX:COV
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cleo Diagnostics ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.013) - (1 + 0 + 0.102)
=-1.089

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.098 + 0 + 0.075999999999999) - (1.006 + 0 + 0.129)
=-0.961

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Cleo Diagnostics for the quarter that ended in Dec. 2025 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-7.58/( ( (0.033 + max(-1.089, 0)) + (0.028 + max(-0.961, 0)) )/ 2 )
=-7.58/( ( 0.033 + 0.028 )/ 2 )
=-7.58/0.0305
=-24,852.46 %

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of -24,852.46% mean?
Cleo Diagnostics (ASX:COV) has a ROC (Joel Greenblatt) % of -24,852.46% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Cleo Diagnostics and its competitors. According to the industry distribution chart, Cleo Diagnostics ranks #833 out of 838 companies in the Medical Devices & Instruments industry, placing it in the top 99.4%.
Is Cleo Diagnostics' ROC (Joel Greenblatt) % too high?
Cleo Diagnostics' current ROC (Joel Greenblatt) % is -24,852.46%. Based on the distribution chart, Cleo Diagnostics ranks #833 out of 838 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Cleo Diagnostics has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Cleo Diagnostics' ROC (Joel Greenblatt) % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Cleo Diagnostics ranks #833 out of 838 companies for ROC (Joel Greenblatt) %. This places Cleo Diagnostics in the lower half of its industry. The industry median ROC (Joel Greenblatt) % is 4.15. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median ROC (Joel Greenblatt) % among Medical Devices & Instruments companies is 4.15, based on 838 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Cleo Diagnostics and its competitors. For the Medical Devices & Instruments industry, the median ROC (Joel Greenblatt) % is 4.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cleo Diagnostics's current ROC (Joel Greenblatt) % is -24,852.46%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cleo Diagnostics stock overvalued right now?
Cleo Diagnostics (ASX:COV) has a current ROC (Joel Greenblatt) % of -24,852.46%. The current ROC (Joel Greenblatt) % is -24,852.46%. Cleo Diagnostics' overall GF Score™ is 10/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Cleo Diagnostics (ASX:COV), the current ROC (Joel Greenblatt) % is -24,852.46% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cleo Diagnostics Business Description

Address 480 Collins Street, Level 2, Melbourne, VIC, AUS, 3000
Cleo Diagnostics Ltd is focused on the development of non-invasive blood-based IVD tests to detect the presence, and recurrence, of ovarian cancer. The company's first product to market is intended to be the Triage Test which results to accurately differentiate patients with malignant ovarian cancer from those with benign gynecological conditions. The company aims to improve the diagnostic process and procedures for detecting ovarian cancer and, in this regard, improve quality-of-life outcomes for patients who have been diagnosed with ovarian cancer.
10GF Score

Get the complete analysis for ASX:COV

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.35
Price